1443530-05-9

Usage

Uses

Used in Pharmaceutical Industry:
4-[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methylpiperazin-2-one is used as a potential pharmaceutical candidate for [specific application reason, if known]. Its unique structure, including the presence of various functional groups, may contribute to its potential therapeutic effects. However, further research is required to fully understand its pharmacological properties and explore its potential uses in treating specific diseases or conditions.

Upstream product

• 83485-34-1 2-methoxy-4-methylbenzenethiol 
• 216394-11-5 2-methoxy-4-methylbenzenesulfonyl chloride 
• 1443531-59-6 1-[(2,2-diethoxyethyl)sulfanyl]-2-methoxy-4-methylbenzene 
• 1388033-29-1 7-methoxy-5-methyl-1-benzothiophene 
• 1443531-60-9 (7-methoxy-5-methyl-1-benzothiophen-2-yl)boronic acid 
• 1443531-61-0 2-(7-methoxy-5-methyl-1-benzothiophen-2-yl)-6-methyl-1,3,6,2-dioxazaborocane-4,8-dione 
• 937049-27-9 4-aminopyrrolo[2,1-f][1,2,4]triazine-6-carbonitrile 
• 939808-08-9 ethyl 4-aminopyrrolo[2,1-f][1,2,4]triazine-6-carboxylate 
• 939807-71-3 4-amino-6-(hydroxymethyl)pyrrolo[2,1-f][1,2,4]triazine 
• 5625-67-2 2-Ketopiperazine 
• 50-00-0 formaldehyd 
• 1443531-77-8 6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine 
• 1443531-65-4 4-amino-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde 
• 1443531-66-5 4-amino-5-bromo-6-(methoxymethyl)pyrrolo[2,1-f][1,2,4]triazine-7-carbaldehyde 

Relevant academic research and scientific papers

THE MONOHYDRATE OF ROGARATINIB HYDROCHLORIDE AND SOLID STATES THEREOF

Compound (III) which is the crystalline form of [4-{[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-l-benzothiophen-2-yl)pyrrolo[2, -f] [ 1,2,4]triazin-7-yl]methyl}piperazin-2-one hydrochloride] which is the monohydrate, processes for its preparation, pharmaceutical compositions comprising it and its use in the control of disorders, including cancer.

Discovery of Rogaratinib (BAY 1163877): a pan-FGFR Inhibitor

Rogaratinib (BAY 1163877) is a highly potent and selective small-molecule pan-fibroblast growth factor receptor (FGFR) inhibitor (FGFR1–4) for oral application currently being investigated in phase 1 clinical trials for the treatment of cancer. In this publication, we report its discovery by de novo structure-based design and medicinal chemistry optimization together with its pharmacokinetic profile.

Disubstituted benzothienyl-pyrrolotriazines and uses thereof

This invention relates to novel substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.

DISUBSTITUTED BENZOTHIENYL-PYRROLOTRIAZINES AND THEIR USE AS FGFR KINASE INHIBITORS

This invention relates to novel substituted 5-(1-benzothiophen-2-yl) pyrrolo[2,1-f][1,2,4]triazin-4-amine derivatives of formula (I) wherein R1 is hydrogen, chloro, methyl or methoxy, R2 is hydrogen or methoxy, with the proviso that at least one of R1 and R2 is other than hydrogen, G1 represents chloro, (C1-C4)-alkyl, (C1-C4)-alkoxycarbonyl, 5-membered aza-heteroaryl, or the group -CH2-OR3, -CH2-NR4R5 or -C(=0)- NR4R6, and G2 represents chloro, cyano, (C1-C4)-alkyl, or the group - CR8AR8B-OH, -CH2-NR9R10, -C(=0)-NR11R12 or -CH2-OR15, having protein tyrosine kinase inhibitory activities, to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating proliferative disorders, in particular cancer and tumor diseases.